Butylscopolamine | Market Size, Share & Growth Report 2025-2034

    The Butylscopolamine Market Report is Segmented by Product Type (Tablet, Injection, Syrup, Gel, and Patch), Application (Gastrointestinal Disorders, Menstrual Disorders, Urinary Disorders, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Ingredient Type (Butylscopolamine Hydrobromide and Butylscopolamine Methylbromide).

    Base Year: 20255 RegionsForecast 2025–2034240 Pages
    Market Size (2025)
    USD 305.0 million
    CAGR
    3.00%
    Forecast Value (2034)
    USD 398.0 million

    Butylscopolamine Market

    3.00% CAGR

    Market Size & Share

    2025 to 2034 forecast analysis

    Market Size (2025)
    USD 305.0 million
    CAGR
    3.00%
    (2025–2034)
    Forecast (2034)
    USD 398.0 million

    Key Findings

    Butylscopolamine reaches USD 398.0 million by 2034

    The global butylscopolamine market was estimated at approximately USD 305.0 million in 2025 and is projected to reach around USD 398.0 million by 2034, a CAGR of approximately 3.00% across 2025-2034, based on Core Market Research estimates. The size covers hyoscine N-butylbromide tablets, combinations and injections.

    One brand family and many generics

    Opella's Buscopan and Buscapina are the originator brands, competing with generic injections and tablets from Europe, China, the United Arab Emirates and India. Raw material comes from Duboisia grown in Australia by Boehringer Ingelheim and processed by makers such as Alkaloids of Australia.

    Abdominal cramp self-treatment sustains demand

    The strongest growth basis is consumer self-treatment of abdominal cramps, supported by paracetamol combinations that raise value per pack. Buscopan is among Opella's principal Western European brands.

    No U.S. approval limits reach

    The principal constraint is the absence of FDA approval for human use, which excludes the United States. In mature markets, an off-patent molecule and generic competition keep growth low.

    Tablets lead the supplied product types

    Within the supplied product types, Tablet leads through Buscopan and its paracetamol combinations, while Injection serves hospitals, imaging and palliative care. Patch products contain scopolamine hydrobromide rather than butylscopolamine.

    Asia Pacific concentrates supply and growth

    Asia Pacific is the largest region on a supply and demand concentration basis, with Australian Duboisia plantations and API production and China's hyoscine market projected to grow 5.4 percent a year to 2030.

    Market Analysis

    How the market stands today, and what is shaping it

    The global butylscopolamine market was estimated at approximately USD 305.0 million in 2025 and is projected to reach around USD 398.0 million by 2034, representing a CAGR of approximately 3.00% during 2025-2034, based on Core Market Research estimates. Butylscopolamine, or hyoscine N-butylbromide, is a smooth-muscle antispasmodic sold mainly as Buscopan and Buscapina tablets, paracetamol combinations and 20 mg/mL injections for hospitals, imaging and palliative care. Growth rests on self-treatment of abdominal cramps, on combination products, on WHO listing of the injection and on rising hospital use in China. Expansion is constrained by the lack of FDA approval for human use, by generic competition for an off-patent molecule and by imaging performance below glucagon. Supply runs through Opella's brands, Boehringer Ingelheim's Australian Duboisia raw material and API makers such as Alkaloids of Australia, so competition turns on brand trust and tender pricing. Asia Pacific concentrates supply and growth, and Opella's April 2025 separation from Sanofi refocuses the leading brands.

    Market Dynamics

    Key market dynamics and their impact on the industry landscape

    Market Drivers

    • Self-treatment of abdominal cramps sustains consumer demand. Opella lists Buscopan among its principal brands in Western Europe, where it is sold through pharmacies for abdominal pain, so recurring cramp episodes can lead to repeat purchases.
    • Fixed-dose combinations add value per pack. Buscopan Plus pairs 10 mg hyoscine N-butylbromide with 500 mg paracetamol, and Buscapina Compositum products combine the two in Latin America, addressing pain and spasm together at a higher price than plain tablets.
    • WHO listing supports hospital procurement. The 2013 addition of the 20 mg/mL injection to the WHO Model List of Essential Medicines for palliative care gives health systems a basis for including butylscopolamine in national formularies and tenders.
    • Brand ownership is being refocused on consumer health. Opella became a standalone company in April 2025, with CD&R holding 50.0 percent, and Buscopan and Buscapina are among its digestive brands, which may sharpen investment in their marketing.
    • Demand is growing fastest in China, where Global Industry Analysts expects the hyoscine market to expand at 5.4 percent a year to 2030, against 1.6 percent in Germany and 1.2 percent in Japan, as hospitals adopt branded and generic injections.

    Market Challenges

    • Hyoscine butylbromide has no FDA approval for human use, excluding the United States from the market.
    • In a 2009 Swiss MRI study, butylscopolamine failed to stop bowel motion in half of cases, against none for glucagon.
    • Patents have expired in most jurisdictions, the WHO notes, exposing the molecule to low-priced generic competition.
    • Scopolamine starting material depends on Duboisia plantations in eastern Australia, concentrating raw material supply in one region.

    Opportunities

    • New fixed-dose combinations with analgesics could extend Buscopan and Buscapina into wider pain indications.
    • Hospital demand in China, growing at a projected 5.4 percent a year, may reward suppliers of injectable butylscopolamine.
    • Palliative care programmes using the WHO-listed injection could expand procurement in lower-income health systems.
    • Use in CT colonography and abdominal MRI may support injection demand where glucagon is costlier or less available.

    Segment Analysis

    Market segmentation by product type, application, distribution channel, ingredient type

    Tablet is the main consumer form, sold as Buscopan 10 mg tablets for abdominal cramps and in fixed-dose combinations with paracetamol, such as Buscopan Plus with 500 mg paracetamol and Colombia's Buscapina Compositum NF with 325 mg. Injection is the hospital form, with 20 mg/mL ampoules listed on the WHO Essential Medicines List for palliative care and used as an antispasmodic in abdominal imaging. Patch products contain scopolamine hydrobromide for motion sickness rather than butylscopolamine, so they sit outside the core molecule. Syrup and Gel forms are niche, and no separate value was identified for either.

    Geography Analysis

    Regional market analysis

    Largest Market
    Asia Pacific
    Fastest Growing
    Asia Pacific

    North America

    North America is a small market for butylscopolamine, because hyoscine butylbromide has no FDA approval for human use in the United States, where methscopolamine, hyoscyamine and dicyclomine are used instead. Global Industry Analysts' USD 115.6 million U.S. hyoscine figure for 2024 therefore reflects other hyoscine forms such as scopolamine hydrobromide. Global Industry Analysts expects Canada's hyoscine market to grow 2.2 percent a year. The regional constraint is regulatory, since the absence of a U.S. approval excludes the largest pharmaceutical market from butylscopolamine sales.

    Europe

    Europe is a core market for Buscopan, which Opella lists among its principal Western European brands alongside Dulcolax and Allegra. Combination products such as Buscopan Plus with paracetamol are sold through pharmacies, including online pharmacies in Austria. Hospitals use butylscopolamine injections in abdominal imaging, studied at the University of Bern against glucagon. Global Industry Analysts expects Germany's hyoscine market to grow about 1.6 percent a year. The regional constraint is maturity, with an off-patent molecule and established brands limiting growth.

    Asia Pacific

    Asia Pacific is the largest region on a supply and demand concentration basis rather than on a published butylscopolamine regional market size. Boehringer Ingelheim grows about 990 hectares of Duboisia in eastern Australia, and Alkaloids of Australia makes hyoscine butylbromide API at Kingaroy, close to the plantations. Global Industry Analysts projects China's hyoscine market to grow at 5.4 percent a year to USD 97.8 million by 2030, faster than Japan at 1.2 percent, and China has tested a branded butylscopolamine injection against anisodamine in a Phase III trial. The regional constraint is price competition from domestic generics.

    Latin America

    Latin America sells butylscopolamine mainly under the Buscapina name, now an Opella brand, including combinations with paracetamol such as Buscapina Compositum N in Argentina and Peru and Buscapina Compositum NF in Colombia. Boehringer Ingelheim studied the combination's use in adults in Lima in 2016. No separate Latin American market size or growth figure was identified in the sources reviewed. The regional constraint is dependence on a single brand family, which leaves pricing exposed to local generic competition.

    Middle East & Africa

    Middle East & Africa uses butylscopolamine injections and tablets in hospitals and pharmacies, and the WHO's 2013 listing of the 20 mg/mL injection supports its inclusion in national essential medicines lists across the region. Generic injections are also offered by manufacturers in the United Arab Emirates. No regional market size, revenue or growth figure was identified in the sources reviewed. The regional constraint is reliance on low-priced generic procurement, which limits value per unit.

    Competitive Landscape

    Key players and market positioning analysis

    Butylscopolamine is an off-patent molecule supplied by one originator brand family and many generic manufacturers, built on a raw material chain concentrated in Australia. Three independent participants could be verified, ordered by the breadth of their role in the market. Opella owns Buscopan and Buscapina, the originator brands, including paracetamol combinations sold across Europe and Latin America, after Sanofi sold a 50.0 percent controlling stake to CD&R in April 2025. Boehringer Ingelheim, which developed Buscopan and sold its consumer business to Sanofi in 2017, has grown about 990 hectares of Duboisia in eastern Australia, according to CSIRO, to supply scopolamine for semi-synthetic anticholinergics. Alkaloids of Australia makes hyoscine butylbromide API at Kingaroy, near those plantations. Generic injections and tablets are made by manufacturers in Europe, China, the United Arab Emirates and India, and in China a branded injection has been compared with anisodamine in a Phase III trial. Competition therefore turns on brand trust in self-medication, price in hospital tenders and access to scopolamine raw material, and positioning may depend on combinations and growth in Chinese hospital use.

    3 companies profiled in this report

    Major Players

    Leading companies in the market

    O
    Opella
    France
    B
    Boehringer Ingelheim International GmbH
    Germany
    A
    Alkaloids of Australia Pty Ltd
    Australia

    Industry Developments

    5 recorded developments

    2025

    Sanofi completed the sale of a 50.0 percent controlling stake in its consumer healthcare business Opella to CD&R on 30 April 2025, keeping 48.2 percent, with Bpifrance holding 1.8 percent. Buscopan and its Latin American counterpart Buscapina became brands of the standalone Opella.

    2017

    Sanofi took over Boehringer Ingelheim's consumer healthcare business, including Buscopan, in January 2017 in exchange for its Merial animal health business. Boehringer Ingelheim continues to source scopolamine from Duboisia hybrid leaf, which a 2014 company paper describes as the starting material for semi-synthetic anticholinergics.

    2016

    Boehringer Ingelheim registered an observational study of Buscapina Compositum N, combining 10 mg hyoscine N-butylbromide with 500 mg paracetamol, in adults in metropolitan Lima, Peru, as NCT02910167. The study examined adverse events and drug utilisation for the combination in Latin America.

    2013

    The WHO added hyoscine butylbromide 20 mg/mL injection to its Model List of Essential Medicines as a core palliative care medicine, to manage respiratory secretions in dying patients. The listing supports its inclusion in national procurement lists, although the WHO committee described the evidence for that use as weak.

    2009

    A Swiss MRI study in 10 healthy volunteers compared hyoscine N-butylbromide with glucagon for stopping small-bowel peristalsis. Aperistalsis lasted a mean 6.8 minutes after butylscopolamine against 18.3 minutes after glucagon, and butylscopolamine failed to achieve aperistalsis in half of cases, defining its limits as an imaging agent.

    Table of Contents

    13 comprehensive chapters

    1. Introduction

    1.1 Market Definition

    1.2 Scope of the Study

    1.3 Research Objectives

    2. Research Methodology

    2.1 Research Approach

    2.2 Data Sources

    2.3 Market Estimation Approach

    2.4 Forecast Assumptions

    2.5 Research Limitations

    3. Executive Summary and Market Overview

    3.1 Market Overview

    3.2 Market Size and Forecast

    3.3 Key Findings

    3.4 Market Structure

    4. Market Dynamics

    4.1 Market Drivers

    4.2 Market Challenges

    4.3 Market Opportunities

    4.4 Market Trends and Insights

    5. Market Segmentation Analysis

    5.1 Market Segmentation Overview

    5.2 By Product Type

    5.3 By Application

    5.4 By Distribution Channel

    5.5 By Ingredient Type

    6. Geographic Analysis

    6.1 North America

    6.2 Europe

    6.3 Asia Pacific

    6.4 Latin America

    6.5 Middle East & Africa

    6.6 Regional Market Comparison

    7. Industry Analysis and Developments

    7.1 Industry Developments

    7.2 Industry Timeline

    8. Competitive Landscape

    8.1 Market Structure and Competitive Positioning

    8.2 Major Players

    8.3 Strategic Developments

    8.4 Key Competitive Factors

    9. Key Player Profiles

    9.1 Opella

    9.2 Boehringer Ingelheim International GmbH

    9.3 Alkaloids of Australia Pty Ltd

    10. Market Outlook and Forecast

    10.1 Market Size and Growth Outlook

    10.2 Regional Market Outlook

    10.3 Future Market Trends

    10.4 Key Risks to the Forecast

    11. Strategic Insights and Market Opportunities

    11.1 Growth Opportunities

    11.2 Key Risks and Constraints

    11.3 Strategic Considerations

    12. Frequently Asked Questions
    13. Appendix and Research References

    13.1 Glossary of Terms

    13.2 Abbreviations

    13.3 Research References

    Scope of the Report

    Report coverage and methodology

    Study Period

    Base Year: 2025
    Forecast Period: 2025 - 2034

    Geographic Scope

    North America, Europe, Asia Pacific, Latin America, Middle East & Africa

    Companies Covered

    Opella, Boehringer Ingelheim International GmbH, Alkaloids of Australia Pty Ltd + more

    Data Sources

    Primary research, industry interviews, regulatory filings, company reports

    Frequently Asked Questions

    Common questions about this report

    The global butylscopolamine market was estimated at approximately USD 305.0 million in 2025, based on Core Market Research estimates.

    Ready to Get the Full Report?

    Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.

    Single User
    $2,500
    Multi User
    $4,000
    Enterprise
    $5,500